Multi-omics Biomarkers

Exploratory biomarker analyses include genomic, transcriptomic, proteomic, metabolomic, and exosome measures from blood and urine, intended to identify treatment responders. Whole genome sequencing of all participants at baseline is intended to identify genomic predictors of bumetanide treatment response. Resting-state EEG is used as an exploratory biomarker to assess network-level excitation/inhibition balance, including power spectral density across theta, alpha, beta, and gamma bands. NKCC1 and KCC2 expression in peripheral blood mononuclear cells is considered a promising biomarker, based on evidence of dysregulation in epilepsy, spinal cord injury, and schizophrenia.